7.8. quality life. 7.8.1. introduction evaluation hrqol considers physical, psychological, emotional social functioning. patients mibc, hrqol affected, particularly physical social functioning domains . several questionnaires validated assessing hrqol patients bc, including fact-g , eortc qlq-c30/blm30 , sf-36 bladder cancer index (bci) . spite validated questionnaires, heterogeneity measurements used assess sexual health. health questionnaire covers entire range sexual health bladder cancer patients currently lacking . regardless questionnaire used, assessment baseline post-treatment hrqol important. questionnaires helpful tools clinical decision making, but, addition, data support prognostic value baseline hrqol . large population-based study patients mibc prior psychiatric history, 31% patients mibc diagnosed new mental health disorder bladder cancer diagnosis . 7.8.2. neoadjuvant chemotherapy two rcts including patiens undergoing nac published hrqol data . huddart et al., analysed subset patients within bc2001 trial underwent nac prior (chemo)radiation. using fact-bl questionnaire, detrimental impact nac hrqol observed . kitamura et al., reported 64 patients included jcog0209 study underwent nac (mvac vs. mvac rc). overall decline hrqol reported directly following nac using fact-bl questionnaire. however, difference hrqol observed consolidating rc. 7.8.3. radical cystectomy urinary diversion two systematic reviews meta-analyses focused hrqol rc urinary diversion . yang et al., compared hrqol incontinent continent urinary diversions (all types) including 29 studies (n = 3,754) 9 prospective design (one randomised) . three studies reported hrqol data pre- post-operatively. three studies reported initial deterioration overall hrqol general health, functional emotional domains 12 months post-surgery equal better baseline. overall, difference hrqol continent incontinent urinary diversion reported although ileal conduit may confer small physical health benefit . cerruto et al., reported hrqol comparing ileal conduit orthotopic neobladder reconstruction . pooled analysis performed including 18 studies (n = 1,553) vast majority retrospective studies. although study hampered methodological limitations, statistical significant difference overall hrqol found. altogether, appears superior type urinary diversion terms overall hrqol rather result proper patient selection. older isolated patient probably better served ileal conduit, whereas younger patient higher level interest body image sexuality better orthotopic diversion. patient’s choice key selection reconstruction method . number rcts comparing orc rarc (with either intra- extracorporeal urinary diversion) reported hrqol data [358,561-563]. studies reported statistical significant difference hrqol outcomes surgical techniques. 7.8.4. adjuvant therapy hrqol data reported phase 3 checkmate 274 rct patients randomised adjuvant nivolumab placebo radical surgery bladder cancer utuc. patients pre-treated nac. clinically meaningful detoration hrqol observed nivolumab treatment (based eortc qlq-c30/vas questionnaire) . 7.8.5. bladder-sparing trimodality therapy hrqol data bladder sparing treatment collected rct setting published huddart et al. . primary endpoint change bladder cancer subscale (blcs), part fact-bl questionnaire, one year post-treatment. questionnaire return rate one five years 70% 60%, respectively. reduction hrqol seen majority domains immediately following rt, however, patients hrqol scores returned baseline 6 months rt maintained level five years. approximately 33% patients reported persistent lower bladder cancer subscale scores five years. addition chemotherapy affect hrqol outcomes. also see section 7.5.4 discussion qol tmt. 7.8.6. non-curative metastatic bladder cancer patients primary non-curative metastastic disease hrqol reduced associated micturition problems, bleeding, pain therefore disturbance social sexual life . beneficial impact palliative surgery , rt , and/or chemotherapy bladder-related symptoms described . hrqol analysis performed platinum-refractory patients randomised pembrolizumab vs. another line chemotherapy (keynote-45 trial) . reported patients treated pembrolizumab stable improved global health status/qol, whereas treated investigators’ choice chemotherapy experienced declines global health . recently, hrqol data presented cohort 1 ev-201 study including 125 patients treated enfortumab vedotin failing previous treatment platinum chemotherapy anti–pd-1/l1 therapy . patients remained enfortumab vedotin treatment showed detoriation hrqol. patients bone metastases baseline, pain control possibly pain reduction observed. 7.8.7. summary evidence recommendations health-related quality life summary evidencelecompared non-cancer controls, diagnosis treatment bc negative impact hrqol.2athere distinct difference overall qol patients continent incontinent diversion.1bin patients mibc treated rc, overall hrqol declines immediately treatment recovers baseline 12 months post-operatively patients.1bin patients mibc treated rt, overall hrqol declines immediately treatment, recovers baseline 6 months post-treatment.1bhrqol data comparable rarc (with either intracorporeal extracorporeal urinary diversion) orc.1bin patients mibc treated rt, concomitant chemotherapy neo-adjuvant chemotherapy significant impact hrqol.1badjuvant treatment nivolumab result clinically meaningful decrease hrqol compared placebo.1bin patients platinum-refractory advanced uc, pembrolizumab may superior terms hrqol compared another line chemotherapy.1b recommendationsstrength ratinguse validated questionnaires assess health-related quality life patients muscle-invasive bladder cancer, baseline post-treatment.strongdiscuss type urinary diversion taking account patient preference, existing comorbidities, tumour variables coping abilities.strong